Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing transferrin receptor 1 (TfR1) and its variants on the cell surface, including but not limited to AML, ALL, lymphoma, multiple myeloma, breast cancer, gastric cancer, glioblastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain and heavy chain variable regions of an anti-TfR1 monoclonal antibody (mAb), MAb11-22.1, which, is highly specific for tumor cells and in an ADC form, can functionally inhibit the proliferation of several human cancer cell lines and the growth of AML cell line-derived xenograft tumors in mouse models.

Abstract: The present invention provides a therapeutic agent for the treatment, prevention and diagnosis of cancers associated with cells that overexpressing podocalyxin-like protein precursor isoform 2 (PODXL-v2) and its variants with deletion of N-terminal serine and proline residues, on the cell surface, including gastric cancers, squamous cell carcinoma of the stomach, gastric adenocarcinoma, small cell carcinoma of the stomach, gastric squamous cell carcinoma, gastric carcinoid tumors, stomach and duodenal cancers, gliobastoma, prostate cancer, urothelial bladder cancer, pancreatic cancer, esophageal cancer, colorectal cancer, ovarian cancer, liver cancer. The agent is based on the amino acid sequences of the novel light chain variable regions of an anti-PODXL-v2 monoclonal antibody (mAb), MAb1738, that can functionally inhibit the proliferation of several human cancer cell lines and the growth and metastasis of gastric cancer in mouse models.